Eli Lilly was once again reported by its competitor Novo Nordisk to IGN (the Information Review Board) for breaching good industry practice in its marketing. A previous complaint was dismissed, as earlier reported.
This time, the criticism is directed at statements made by Patrik Jönsson, Executive Vice President Lilly International, in an interview with Swedish business daily Dagens Industri. In the interview, he commented on retatrutide, a drug under development for the treatment of obesity and type 2 diabetes.
BREAKING